Thalidomide and hematopoietic-cell transplantation for multiple myeloma

New England Journal of Medicine

Volumn 354, Issue 10, 2006, Pages 1021-1030

  Barlogie, Bart ^a   Tricot, Guido ^a   Anaissie, Elias ^a   Shaughnessy, John ^a   Rasmussen, Erik ^b   Van Rhee, Frits ^a   Fassas, Athanasios ^a   Zangari, Maurizio ^a   Hollmig, Klaus ^a   Pineda Roman, Mauricio ^a   Lee, Choon ^a   Talamo, Giampaolo ^a   Thertulien, Raymond ^a   Kiwan, Elias ^a   Krishna, Somashekar ^a   Fox, Michele ^a   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THROMBOEMBOLISM; TREMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; SURVIVAL RATE; THALIDOMIDE;

EID: 33644833147     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa053583     Document Type: Article

References (37)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
3. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
5. [Erratum, N Engl J Med 2004;350:2628.]
6. Cavo M, Cellini C, Zamagni E. Update on high-dose therapy - Italian studies. Haematologica 2005;90:Suppl 1:39. abstract.
7. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
8. [Erratum, N Engl J Med 2000;342:364.]
9. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
10. Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Haematol 2003;120:44-52.
11. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
12. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9.
13. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985;76:765-9.
14. Crowley J, Green S, Liu PY, Wolf M. Data monitoring committees and early stopping guidelines: the Southwest Oncology Group experience. Stat Med 1994;13:1391-9.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
19. Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-20.
20. [Erratum, J Clin Oncol 2005;23:6281. ]
21. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
22. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
23. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Blood 2004;104:155a. abstract.
24. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 1989;110:521-5.
25. Barlogie B, Shaughnessy J Jr, Epstein J. Plasma cell myeloma. In: Beutler E, Licht man M, Coller B, Kipps T, Seligsohn U, eds. Williams hematology. 7th ed. New York: McGraw-Hill, 2005:1501-33.
26. Fassas A, Barlogie B, Rasmussen E, et al. Low incidence of complete remission but comparable event-free survival (EFS) and overall survival (OS) with a history of prior monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (Smultiple myeloma) among patients receiving total therapy 2 (TT 2). Blood 2004;104:924. abstract.
27. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
28. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
29. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-71.
30. Palumbo A, Bertola A, Pellegrino M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005;104:1428-33.
31. Palumbo A, Bertola A, Musto P, et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood 2004;104:63a. abstract.
32. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
33. Harousseau J-L, Attal M, Leleu X, et al. Bortezomib (Velcade) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Blood 2004;104:416a. abstract.
34. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-65.
35. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
36. Alexanian R, Wang L, Weber D, et al. VTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood 2004;104:98a. abstract.
37. Sawyers CL. Calculated resistance in cancer. Nat Med 2005;11:824-5.